Pharmerging Market (Product Type: Pharmaceuticals and Healthcare; and Indication: Lifestyle Diseases, Cancer and Autoimmune Diseases, Infectious Diseases, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
파머징(Pharmerging) 시장- 조사 범위
TMR의 조사 보고서 "파머징(Pharmerging) 세계 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측연도로 삼아 2018년부터 2034년까지 세계 파머징(Pharmerging) 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 파머징(Pharmerging) 시장의 연평균 복합 성장률(CAGR%)도 제시합니다.
이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하고, 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 등을 참조하여 작성되었습니다.
| 시장 현황 |
| 2023년 시장 규모 |
21억 달러 |
| 2034년 시장 가치 |
71억 달러 |
| CAGR |
11.6% |
이 보고서는 세계 파머징(Pharmerging) 시장 경쟁 구도에 대해 심층적으로 분석합니다. 세계 제약 시장에서 활동하는 주요 기업들을 식별하고, 각 기업들은 다양한 속성에 따라 프로파일을 작성했습니다. 기업 개요, 재무 상태, 최근 동향, SWOT는 이 보고서에서 다루는 세계 제약 시장 기업의 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 시장
제4장 시장 개요
- 서론
- 시장 개요
- 시장 역학
- 시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
- 파이프라인 분석
- 주요 제품 유형/브랜드 분석
- 주요 M&A
- COVID-19 팬데믹의 산업에 대한 영향
제6장 세계 시장 분석과 예측 : 제품 유형별
- 서론과 정의
- 주요 조사 결과/발전
- 시장 매출 예측 : 제품 유형별, 2020-2034년
- 의약품
- 브랜드 처방약
- 제네릭 의약품
- 브랜드 제네릭 의약품
- 브랜드 없는 제네릭 의약품
- OTC 의약품
- 헬스케어
- 시장의 매력 분석 : 제품 유형별
제7장 세계 시장 분석과 예측 : 적응증별
- 서론과 정의
- 주요 조사 결과/발전
- 시장 매출 예측 : 적응증별, 2020년-2034년
- 시장의 매력 분석 : 적응증별
제8장 세계 시장 분석과 예측 : 유통 채널별
- 서론과 정의
- 주요 조사 결과/발전
- 시장 매출 예측 : 유통 채널별, 2020년-2034년
- 병원
- 진료소
- 소매 약국
- E-Commerce
- 드럭스토어
- 시장의 매력 분석 : 유통 채널별
제9장 세계 시장 분석과 예측 : 지역별
- 주요 조사 결과
- 시장 매출 예측 : 지역별, 2020-2034
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- 시장의 매력 분석 : 지역별
제10장 유럽 시장 분석과 예측
제11장 아시아태평양 시장 분석과 예측
제12장 라틴아메리카 시장 분석과 예측
제13장 중동 및 아프리카 시장 분석과 예측
제14장 경쟁 구도
- 시장 경쟁 매트릭스(기업 Tier별, 기업 규모별)
- 시장 점유율 분석 : 기업별(2023년)
- 기업 개요
- Abbott Laboratories
- Koninklijke Philips N.V.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Novartis AG
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- AstraZeneca
- GlaxoSmithKline plc
- Lupin
- Tata Consultancy Services Ltd.
- Sun Pharmaceutical Industries Ltd.
- Huadong Medicine Co., Ltd.
LSH
Pharmerging Market - Scope of Report
TMR's report on the global pharmerging market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global pharmerging market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pharmerging market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the pharmerging market.
| Market Snapshot |
|---|
| Market Value in 2023 | US$ 2.1 Bn |
| Market Value in 2034 | US$ 7.1 Bn |
| CAGR | 11.6% |
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pharmerging market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pharmerging market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pharmerging market.
The report delves into the competitive landscape of the global pharmerging market. Key players operating in the global pharmerging market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pharmerging market profiled in this report.
Key Questions Answered in Global pharmerging Market Report:
- What is the sales/revenue generated by pharmerging across all regions during the forecast period?
- What are the opportunities in the global pharmerging market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2034?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Pharmerging Market - Research Objectives and Research Approach
The comprehensive report on the global pharmerging market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global pharmerging market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pharmerging market.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Pharmerging Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Product Type Definition
- 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Pharmerging Market Analysis and Forecast, 2020-2034
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Key Product Type /Brand Analysis
- 5.3. Key Mergers & Acquisitions
- 5.4. COVID-19 Pandemic Impact on Industry
6. Global Pharmerging Market Analysis and Forecast, by Product Type
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Product Type, 2020-2034
- 6.3.1. Pharmaceuticals
- 6.3.1.1. Branded Prescription Drugs
- 6.3.1.2. Generic Drugs
- 6.3.1.2.1. Branded Generics
- 6.3.1.2.2. Unbranded Generics
- 6.3.1.3. OTC Drugs
- 6.3.2. Healthcare
- 6.3.2.1. Medical Devices
- 6.3.2.2. Diagnostic Instruments
- 6.3.2.3. Others (IT and Record Management)
- 6.4. Market Attractiveness Analysis, by Product Type
7. Global Pharmerging Market Analysis and Forecast, by Indication
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Indication, 2020-2034
- 7.3.1. Lifestyle Diseases
- 7.3.2. Cancer and Autoimmune Diseases
- 7.3.3. Infectious Diseases
- 7.3.4. Others
- 7.4. Market Attractiveness Analysis, by Indication
8. Global Pharmerging Market Analysis and Forecast, by Distribution Channel
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
- 8.3.1. Hospitals
- 8.3.2. Clinics
- 8.3.3. Retail Pharmacies
- 8.3.4. E-commerce
- 8.3.5. Drugs Stores
- 8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Pharmerging Market Analysis and Forecast, by Region
- 9.1. Key Findings
- 9.2. Market Value Forecast, by Region, 2020-2034
- 9.2.1. Europe
- 9.2.2. Asia Pacific
- 9.2.3. Latin America
- 9.2.4. Middle East & Africa
- 9.3. Market Attractiveness Analysis, by Region
10. Europe Pharmerging Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Key Findings
- 10.3. Market Value Forecast, by Product Type, 2020-2034
- 10.3.1. Pharmaceuticals
- 10.3.1.1. Branded Prescription Drugs
- 10.3.1.2. Generic Drugs
- 10.3.1.2.1. Branded Generics
- 10.3.1.2.2. Unbranded Generics
- 10.3.1.3. OTC Drugs
- 10.3.2. Healthcare
- 10.3.2.1. Medical Devices
- 10.3.2.2. Diagnostic Instruments
- 10.3.2.3. Others (IT and Record Management)
- 10.4. Market Value Forecast, by Indication, 2020-2034
- 10.4.1. Lifestyle Diseases
- 10.4.2. Cancer and Autoimmune Diseases
- 10.4.3. Infectious Diseases
- 10.4.4. Others
- 10.5. Market Value Forecast, by Distribution Channel, 2020-2034
- 10.5.1. Hospitals
- 10.5.2. Clinics
- 10.5.3. Retail Pharmacies
- 10.5.4. E-commerce
- 10.5.5. Drugs Stores
- 10.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 10.6.1. Germany
- 10.6.2. U.K.
- 10.6.3. France
- 10.6.4. Italy
- 10.6.5. Spain
- 10.6.6. Rest of Europe
- 10.7. Market Attractiveness Analysis
- 10.7.1. By Product Type
- 10.7.2. By Indication
- 10.7.3. By Distribution Channel
- 10.7.4. By Country/Sub-region
11. Asia Pacific Pharmerging Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Key Findings
- 11.3. Market Value Forecast, by Product Type, 2020-2034
- 11.3.1. Pharmaceuticals
- 11.3.1.1. Branded Prescription Drugs
- 11.3.1.2. Generic Drugs
- 11.3.1.2.1. Branded Generics
- 11.3.1.2.2. Unbranded Generics
- 11.3.1.3. OTC Drugs
- 11.3.2. Healthcare
- 11.3.2.1. Medical Devices
- 11.3.2.2. Diagnostic Instruments
- 11.3.2.3. Others (IT and Record Management)
- 11.4. Market Value Forecast, by Indication, 2020-2034
- 11.4.1. Lifestyle Diseases
- 11.4.2. Cancer and Autoimmune Diseases
- 11.4.3. Infectious Diseases
- 11.4.4. Others
- 11.5. Market Value Forecast, by Distribution Channel, 2020-2034
- 11.5.1. Hospitals
- 11.5.2. Clinics
- 11.5.3. Retail Pharmacies
- 11.5.4. E-commerce
- 11.5.5. Drugs Stores
- 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 11.6.1. China
- 11.6.2. India
- 11.6.3. Rest of Asia Pacific
- 11.7. Market Attractiveness Analysis
- 11.7.1. By Product Type
- 11.7.2. By Indication
- 11.7.3. By Distribution Channel
- 11.7.4. By Country/Sub-region
12. Latin America Pharmerging Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Key Findings
- 12.3. Market Value Forecast, by Product Type, 2020-2034
- 12.3.1. Pharmaceuticals
- 12.3.1.1. Branded Prescription Drugs
- 12.3.1.2. Generic Drugs
- 12.3.1.2.1. Branded Generics
- 12.3.1.2.2. Unbranded Generics
- 12.3.1.3. OTC Drugs
- 12.3.2. Healthcare
- 12.3.2.1. Medical Devices
- 12.3.2.2. Diagnostic Instruments
- 12.3.2.3. Others (IT and Record Management)
- 12.4. Market Value Forecast, by Indication, 2020-2034
- 12.4.1. Lifestyle Diseases
- 12.4.2. Cancer and Autoimmune Diseases
- 12.4.3. Infectious Diseases
- 12.4.4. Others
- 12.5. Market Value Forecast, by Distribution Channel, 2020-2034
- 12.5.1. Hospitals
- 12.5.2. Clinics
- 12.5.3. Retail Pharmacies
- 12.5.4. E-commerce
- 12.5.5. Drugs Stores
- 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 12.6.1. Brazil
- 12.6.2. Mexico
- 12.6.3. Rest of Latin America
- 12.7. Market Attractiveness Analysis
- 12.7.1. By Product Type
- 12.7.2. By Indication
- 12.7.3. By Distribution Channel
- 12.7.4. By Country/Sub-region
13. Middle East & Africa Pharmerging Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Key Findings
- 13.3. Market Value Forecast, by Product Type, 2020-2034
- 13.3.1. Pharmaceuticals
- 13.3.1.1. Branded Prescription Drugs
- 13.3.1.2. Generic Drugs
- 13.3.1.2.1. Branded Generics
- 13.3.1.2.2. Unbranded Generics
- 13.3.1.3. OTC Drugs
- 13.3.2. Healthcare
- 13.3.2.1. Medical Devices
- 13.3.2.2. Diagnostic Instruments
- 13.3.2.3. Others (IT and Record Management)
- 13.4. Market Value Forecast, by Indication, 2020-2034
- 13.4.1. Lifestyle Diseases
- 13.4.2. Cancer and Autoimmune Diseases
- 13.4.3. Infectious Diseases
- 13.4.4. Others
- 13.5. Market Value Forecast, by Distribution Channel, 2020-2034
- 13.5.1. Hospitals
- 13.5.2. Clinics
- 13.5.3. Retail Pharmacies
- 13.5.4. E-commerce
- 13.5.5. Drugs Stores
- 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 13.6.1. GCC Countries
- 13.6.2. South Africa
- 13.6.3. Rest of Middle East & Africa
- 13.7. Market Attractiveness Analysis
- 13.7.1. By Product Type
- 13.7.2. By Indication
- 13.7.3. By Distribution Channel
- 13.7.4. By Country/Sub-region
14. Competition Landscape
- 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
- 14.2. Market Share Analysis, by Company (2023)
- 14.3. Company Profiles
- 14.3.1. Abbott Laboratories
- 14.3.1.1. Company Overview
- 14.3.1.2. Product Type Portfolio
- 14.3.1.3. SWOT Analysis
- 14.3.1.4. Financial Overview
- 14.3.1.5. Strategic Overview
- 14.3.2. Koninklijke Philips N.V.
- 14.3.2.1. Company Overview
- 14.3.2.2. Product Type Portfolio
- 14.3.2.3. SWOT Analysis
- 14.3.2.4. Financial Overview
- 14.3.2.5. Strategic Overview
- 14.3.3. F. Hoffmann-La Roche Ltd.
- 14.3.3.1. Company Overview
- 14.3.3.2. Product Type Portfolio
- 14.3.3.3. SWOT Analysis
- 14.3.3.4. Financial Overview
- 14.3.3.5. Strategic Overview
- 14.3.4. Merck & Co., Inc.
- 14.3.4.1. Company Overview
- 14.3.4.2. Product Type Portfolio
- 14.3.4.3. SWOT Analysis
- 14.3.4.4. Financial Overview
- 14.3.4.5. Strategic Overview
- 14.3.5. Novartis AG
- 14.3.5.1. Company Overview
- 14.3.5.2. Product Type Portfolio
- 14.3.5.3. SWOT Analysis
- 14.3.5.4. Financial Overview
- 14.3.5.5. Strategic Overview
- 14.3.6. Johnson & Johnson
- 14.3.6.1. Company Overview
- 14.3.6.2. Product Type Portfolio
- 14.3.6.3. SWOT Analysis
- 14.3.6.4. Financial Overview
- 14.3.6.5. Strategic Overview
- 14.3.7. Teva Pharmaceutical Industries Ltd.
- 14.3.7.1. Company Overview
- 14.3.7.2. Product Type Portfolio
- 14.3.7.3. SWOT Analysis
- 14.3.7.4. Financial Overview
- 14.3.7.5. Strategic Overview
- 14.3.8. AstraZeneca
- 14.3.8.1. Company Overview
- 14.3.8.2. Product Type Portfolio
- 14.3.8.3. SWOT Analysis
- 14.3.8.4. Financial Overview
- 14.3.8.5. Strategic Overview
- 14.3.9. GlaxoSmithKline plc
- 14.3.9.1. Company Overview
- 14.3.9.2. Product Type Portfolio
- 14.3.9.3. SWOT Analysis
- 14.3.9.4. Financial Overview
- 14.3.9.5. Strategic Overview
- 14.3.10. Lupin
- 14.3.10.1. Company Overview
- 14.3.10.2. Product Type Portfolio
- 14.3.10.3. SWOT Analysis
- 14.3.10.4. Financial Overview
- 14.3.10.5. Strategic Overview
- 14.3.11. Tata Consultancy Services Ltd.
- 14.3.11.1. Company Overview
- 14.3.11.2. Product Type Portfolio
- 14.3.11.3. SWOT Analysis
- 14.3.11.4. Financial Overview
- 14.3.11.5. Strategic Overview
- 14.3.12. Sun Pharmaceutical Industries Ltd.
- 14.3.12.1. Company Overview
- 14.3.12.2. Product Type Portfolio
- 14.3.12.3. SWOT Analysis
- 14.3.12.4. Financial Overview
- 14.3.12.5. Strategic Overview
- 14.3.13. Huadong Medicine Co., Ltd.
- 14.3.13.1. Company Overview
- 14.3.13.2. Product Type Portfolio
- 14.3.13.3. SWOT Analysis
- 14.3.13.4. Financial Overview
- 14.3.13.5. Strategic Overview
